She advises life sciences and technology companies with respect to corporate finance, SEC reporting and governance matters. Amanda has represented issuers and underwriters in a wide variety of public and private financing transactions, including initial public offerings, follow-on and secondary offerings, SPACs, at-the-market offerings, private investment in public equity (PIPEs), and preferred stock and debt financings.

Amanda also advises late-stage private companies with respect to general corporate governance and liquidity preparation and public companies on corporate and securities law compliance and disclosure matters, including corporate governance best practices, Exchange Act reporting obligations and stock exchange requirements.

Chambers USA ranks Amanda as a top capital markets lawyer. In 2022, Amanda was highlighted by The Legal 500 as among the leading lawyers in U.S. capital markets and healthcare: life sciences.